Follow-up to REDUCE study shows low rate of prostate cancer diagnosis

(Elsevier Health Sciences) The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug's effectiveness. Results from a follow-up study are now published in the Journal of Urology.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news